Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy
Sign Up to like & getrecommendations! Published in 2025 at "Heart Failure Reviews"
DOI: 10.1007/s10741-025-10502-5
Abstract: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the pathological deposition of misfolded transthyretin (TTR) protein in the myocardium, leading to restrictive cardiomyopathy and heart failure. While TTR stabilizers such as tafamidis… read more here.
Keywords: modulating therapies; novel gene; amyloid cardiomyopathy; gene modulating ... See more keywords